MedTrace Logo

Jin-shui Huan-xian Granule in the Treatment of IPF

NCT04187690 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 312

Last updated 2022-08-18

No results posted yet for this study

Summary

This study is to evaluate the efficacy and safety of Jin-shui Huan-xian granule for idiopathic pulmonary fibrosis (IPF), establish the treatment scheme, and obtain the high quality clinical evidences.

Conditions

Interventions

DRUG

Jin-shui Huan-xian granule

Jin-shui Huan-xian granule will be administered 5days on and 2 days off for 52 weeks.

DRUG

Jin-shui Huan-xian granule placebo

Jin-shui Huan-xian granule placebo will also be administered 5days on and 2 days off for 52 weeks. The placebo consists 5% of the same components as Jin-shui Huan-xian granule besides dextrin and bitter. The There is no obvious difference in appearance, weight and odor between Jin-shui Huan-xian granule and placebo.

Sponsors & Collaborators

  • Henan University of Traditional Chinese Medicine

    lead OTHER

Principal Investigators

  • Jian-sheng Li, Professor · The First Affiliated Hospital of Henan University of Traditional Chinese Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2023-05-31
Completion
2023-07-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04187690 on ClinicalTrials.gov